Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development
13 août 2024 07h30 HE
|
Psyence Biomedical Ltd.
VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics...
Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC
31 juil. 2024 16h05 HE
|
Psyence Biomedical Ltd.
NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has entered into a $25 million common stock purchase...
Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
24 juil. 2024 16h05 HE
|
Psyence Biomedical Ltd.
Trial projected to be initiated shortly following receipt of drug product by trial sites NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the...
Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
03 juil. 2024 20h34 HE
|
Psyence Biomedical Ltd.
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that it received a notification letter dated June 27, 2024, from the Listings...
Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase
17 mai 2024 07h00 HE
|
Psyence Biomedical Ltd.
NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that management will host 1x1 meetings with investors during the...
Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)
17 avr. 2024 08h00 HE
|
Psyence Biomedical Ltd.
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that details of its upcoming Phase IIb clinical trial of...
Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
08 avr. 2024 08h00 HE
|
Psyence Biomedical Ltd.
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that its Australian subsidiary, Psyence Australia Pty Ltd....
Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin
18 mars 2024 16h05 HE
|
Psyence Biomedical Ltd.
The study, published in the journal Molecular Psychiatry, suggests that nature-derived psilocybin may be demonstrably more therapeutic than its synthetic analog Benefits are thought to include a...
Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares
15 mars 2024 16h30 HE
|
Psyence Biomedical Ltd.
NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on March 11, 2024, it received two letters from the listing qualifications...
Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones
12 mars 2024 07h00 HE
|
Psyence Biomedical Ltd.
TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental...